The Conversation (0)
Axonics Modulation Technologies (NASDAQ:AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation devices for the treatment of urinary and bowel dysfunction, announced today the publication of a Medtech Innovation Briefing by The National Institute for Health and Care Excellence following a careful review of the innovations offered by the Axonics …
Axonics Modulation Technologies (NASDAQ:AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation devices for the treatment of urinary and bowel dysfunction, announced today the publication of a Medtech Innovation Briefing by The National Institute for Health and Care Excellence following a careful review of the innovations offered by the Axonics System.
As quoted in the press release:
The NICE Medtech Innovation Briefing entitled: “Axonics rechargeable sacral neuromodulation system for overactive bladder and faecal incontinence,” describes published clinical evidence on the Axonics r-SNM System®, confirming efficacy as well as the potential positive economic impact that is possible by the use of the Axonics system in the United Kingdom.
The Axonics r-SNM System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe and commercially available to all hospitals and clinics in the U.K. for patients suffering from urinary and fecal dysfunction. It is estimated that approximately 1,200 patients receive a Sacral Neuromodulation implant in the U.K. every year.